[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612132":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":10,"responsibleParty":27,"collaborators":10,"id":29,"slug":30,"hasResults":31,"nctId":32,"briefTitle":33,"officialTitle":34,"acronym":10,"eligibilityCriteria":35,"healthyVolunteers":31,"sex":36,"minAge":37,"maxAge":10,"enrollmentInfo":38,"targetDuration":10,"studyType":41,"phases":10,"briefSummary":42,"conditions":43,"keywords":45,"overallStatus":51,"whyStopped":10,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":10},{"fullName":5,"class":6},"Gruppo Italiano Malattie EMatologiche dell'Adulto","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"MF patients treated with momelotinib",null,"Patients diagnosed with primary or post-polycythemia vera\u002Fpost-essential thrombocythemia myelofibrosis treated with momelotinib according to clinical practice from AIFA authorization.",[13],{"name":14,"affiliation":15,"role":16},"Francesco Passamonti","Ematologia, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano","PRINCIPAL_INVESTIGATOR",[18,23],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},"Paola Fazi","CONTACT","+390670390528","p.fazi@gimema.it",{"name":24,"role":20,"phone":25,"phoneExt":10,"email":26},"Enrico Crea","+390670390514","e.crea@gimema.it",{"type":28,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100612132","momelotinib-effectiveness-in-myelofibrosis-100612132",false,"NCT07249606","Momelotinib Effectiveness in Myelofibrosis","Real-world Observation of Momelotinib Effectiveness in Myelofibrosis (ROME)","Inclusion Criteria:\n\n1. Patients aged 18 years or older.\n2. Patients diagnosed with primary or post-polycythemia vera\u002Fpost-essential thrombocythemia myelofibrosis start treatment with MMB according to clinical practice from AIFA authorization.\n3. Patients with palpable splenomegaly at baseline of momelotinib treatment.\n4. Informed consent signed, if applicable.\n\nExclusion Criteria:\n\n1. Diagnosis of MPN, unclassifiable, myelodysplastic\u002Fmyeloproliferative neoplasms, myelodysplastic syndromes, essential thrombocythemia, polycythemia vera.\n2. Accelerated\u002Fblast phase of MF.\n3. Patients with platelets \\\u003C20 x10(9)\u002FL at baseline of MMB treatment.\n4. Patients JAK inhibitors-exposed for other diseases apart from MF.","ALL","18 Years",{"count":39,"type":40},93,"ESTIMATED","OBSERVATIONAL","Observational study aimed at evaluating the use of momelotinib in patients with primary or post polycythemia vera (PV) or post essential thrombocythemia myelofibrosis (post-ET MF) in a real-world setting.",[44],"Myelofibrosis (MF)",[46,47,48,49,50],"Myelofibrosis","momelotinib","real-world","post polycythemia","post essential thrombocythemia","NOT_YET_RECRUITING","2025-11-18",{"date":54,"type":55},"2025-11-25","ACTUAL",{"date":57,"type":40},"2026-01-02",{"date":59,"type":40},"2028-04-02",{"name":5,"class":6}]